HIT Consultant April 15, 2021
Zach Henderson, Chief Commercial Officer, Glooko

As with so many aspects of our daily lives, the impact of the COVID-19 pandemic on clinical trials was both widespread and monumental. Thousands of trials—an estimated 80% of non-COVID-19 trials—came to a halt or were interrupted by the pandemic, which challenged the ability to conduct trials safely and effectively and was complicated by the reality that trials often deal with the populations most at risk from COVID-19 exposure1.

In response, clinical researchers turned to a range of solutions to address the effects of the pandemic on trials. And while, in most cases, it’s premature to definitively determine which solutions will outlast the pandemic, probably the most widely used and enduring will be the decentralized model for conducting clinical trials,...

Today's Sponsors

Teladoc Health
Premier
TripleTree

Today's Sponsors

SalesSparx
Canton & Company

Today's Sponsor

HLTH

 
Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health
NIH to test repurposing up to 7 drugs to treat COVID-19 symptoms at home
Genetic Data Identifies Drug Targets to Treat Early COVID-19
Spurred by the pandemic, AI is driving decentralized clinical trials
The Future Of Clinical Trials: How AI, Big Tech, & Covid-19 Could Make Drug Development Cheaper, Faster, & More Effective
5 AI lessons from pharma world learned during Covid-19